Ardelyx Suffers Legal Setback as Appeals Court Confirms XPHOZAH in Medicare Bundle
Ardelyx shares fell after losing a court case on Xphozah Medicare coverage, moving drug into bundled payments, hurting revenue outlook.
/ 2 items
Ardelyx shares fell after losing a court case on Xphozah Medicare coverage, moving drug into bundled payments, hurting revenue outlook.
Ardelyx shares jumped after strong Ibsrela guidance, multiple analyst upgrades, higher price targets, and a faster path to $1B in revenue.